ArticleJournal of hematology & oncology2024
Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant.
Article in Journal of hematology & oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Aggressive Thyroid Carcinomas Clinical and Molecular Features: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Rationale for Testing TP53 Mutations in Thyroid Cancer-Original Data and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Tripartite motif containing 21 autoimmunity primes CD8Arthritis research & therapy · 2026Article
- In Vivo mRNA-Lipid Nanoparticle CAR-T Cell Engineering: Advances, Challenges, and Clinical Translation.Biomedicines · 2026Review
- Single-cell profiling reveals reprogrammed hierarchy and disrupted immune-stromal ecosystem in TP53-mutated AML.Experimental hematology & oncology · 2026Article
- Single-cell RNA sequencing: enhancing the predictive accuracy of tumor immunotherapy efficacy.Essays in biochemistry · 2025Review
- DNA Vaccines in the Post-mRNA Era: Engineering, Applications, and Emerging Innovations.International journal of molecular sciences · 2025Review
- Polymeric immunoglobulin receptor (pIgR) in cancer progression: a critical role and potential therapeutic target.Apoptosis : an international journal on programmed cell death · 2025Review
- Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches.Signal transduction and targeted therapy · 2025Review
- Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies.Antibodies (Basel, Switzerland) · 2025Review
- Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity.Molecular cancer · 2025Article
- Expanding nucleic acid-encoded medicine.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundp53, the most frequently mutated gene in cancer, lacks effective targeted drugs.
methodsWe developed monoclonal antibodies (mAbs) that target a p53 hotspot mutation E285K without cross-reactivity with wild-type p53. They were delivered using lipid nanoparticles (LNPs) that encapsulate DNA plasmids. Western blot, BLI, flow cytometry, single-cell sequencing (scRNA-seq), and other methods were employed to assess the function of mAbs in vitro and in vivo.
resultsThese LNP-pE285K-mAbs in the IgG1 format exhibited a robust anti-tumor effect, facilitating the infiltration of immune cells, including CD8
conclusionsTargeting specific mutant epitopes using DNA-encoded and LNP-delivered mAbs represents a potential precision medicine strategy against p53 mutants in TRIM21- or PIGR-positive cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.